Giorgio Minotti

CIR and Drug Sciences

University Campus Bio-Medico

Via Alvaro del Portillo 21

00128 Rome - Italy

Phone 011-39-06-225419109

FAX 011-39-06-22541456

[email protected]

Home : 5, Monticelli

00197 Rome

Phone : 011-39-06-3202967

EDUCATION

1970-1975 Humanities

1975-1981 M.D. (cum laude)

Catholic University, Rome, Italy.

1981-1984 Residency

Catholic University, Rome,

Major field : Oncology

ACADEMIC POSITION

● Professor of Pharmacology, University Campus Bio-Medico of Rome

RELEVANT WORK EXPERIENCE

● 1981-1988 : Postdoctoral Fellow, Dept. of Pathology, Catholic University School of Medicine, Rome

● September 1985-March 1987 : Fellow of the Italian Association for Cancer Research and Fulbright Scholar, Department of Biochemistry and Center for the Study of Active Oxygen in Biology and Medicine, Michigan State University, East Lansing MI, USA

● June 1990-June 1991 : Fulbright Visiting Professor, Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA

RESEARCH INTERESTS

● Cardiotoxicity of antitumor drugs

● Preclinical models of cardiotoxicity

● Phase I-II clinical research

EDITORIAL ACTIVITY

● Associate Editor

Cardiovascular Toxicology

● Editorial Board Member

Chemical Research in Toxicology

J. Pharmacol. Exptl. Ther.

Redox Reports

RECENT PUBLICATIONS

F. Cacciapaglia F, P. Menna, L. Navarini, A. Afeltra, E. Salvatorelli, G. MINOTTI (2011) Matters of the heart: The case of TNF-alpha targeting drugs.

Mol Interv. 11, 79-87.

F. Cacciapaglia F, L. Navarini, P. Menna, E. Salvatorelli, G. MINOTTI, A. Afeltra (2011) Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues.

Autoimmun. Rev. 10, 631-635

A.M. Tsimberidou AM, G. MINOTTI, D. Cardinale (2011) Managing cardiac risk factors in oncology clinical trials.

Tex. Heart Inst. J. 38, 266-267.

E. Salvatorelli, P. Menna, S. Surapaneni, S.L. Aukerman, M. Chello, E. Covino, V. Sung, G. MINOTTI

(2012) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin. J. Pharmacol. Exptl. Ther. 341, 464-473

E. Salvatorelli, P. Menna, O. Gonzalez Paz, S. Surapaneni, S.L. Aukerman, M. Chello, E. Covino, V. Sung, G. MINOTTI (2012) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. J. Pharmacol. Exptl. Ther. 341, 444-483

P. Menna, O. Gonzalez Paz, M. Chello, E. Covino, E. Salvatorelli, G. MINOTTI (2012) Anthracycline cardiotoxicity.

Expert Opin. Drug Saf. 11, 21-36

E. Salvatorelli, M. De Tursi, M. Pierantonio, S. Carella, R. Massari, A. Colasante, S. Iacobelli. G. MINOTTI (2012) Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermicintraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis Drug Metab. Dispos. 40, 2365-2373.

E. Salvatorelli, P. Menna, O. Gonzalez Paz, M. Chello, E. Covino, J.W. Singer, G. MINOTTI (2013) The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients.

J Pharmacol Exp Ther. 344, 467-478

G. Minotti (2013) Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs.

J Pharmacol Exp Ther. 346, 343-349

Girotti AW, G. MINOTTI (2013) Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs. Development of a tumor-specific photoactivatable Doxorubicin prodrug.

Photochem. Photobiol. 89, 1009-1010.

Cacciapaglia. F, Salvatorelli. E., Minotti G., Afeltra A., Menna P. (2014) Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. Cardiovasc Toxicol. May 6. [Epub ahead of print]

Menna P., Gallo P., Vespasiani Gentilucci U., Salvatorelli E., Galati. G, Minotti G., Picardi A. (2014) Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship. J. Viral. Hepat. Jun 16. doi: 10.1111/jvh.12264. [Epub ahead of print]